Skip to Content

Durable Responses and Stable Disease in Multiple ATM-Altered Advanced Cancers

In this MEDtalk, Martin Højgaard presents the efficacy of camonsertib monotherapy in the subset of patients with advanced cancers harboring ataxia telangiectasia-mutated (ATM) kinase loss-of-function (LoF) (TRESR study). Camonsertib is a selective oral inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with demonstrated efficacy in tumors with DNA damage response gene deficiencies. The study shows that patients with bi-allelic ATM loss had better clinical outcomes, with a 48% clinical benefit rate and some long-lasting responses.
Bi-allelic inactivation, particularly in germline mutations, was a key factor in positive responses.

Martin Højgaard

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top